CA3101102A1 - Inhalable liposomal sustained release composition for use in treating pulmonary diseases - Google Patents
Inhalable liposomal sustained release composition for use in treating pulmonary diseases Download PDFInfo
- Publication number
- CA3101102A1 CA3101102A1 CA3101102A CA3101102A CA3101102A1 CA 3101102 A1 CA3101102 A1 CA 3101102A1 CA 3101102 A CA3101102 A CA 3101102A CA 3101102 A CA3101102 A CA 3101102A CA 3101102 A1 CA3101102 A1 CA 3101102A1
- Authority
- CA
- Canada
- Prior art keywords
- liposomal
- drug
- mol
- sustained release
- release composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661217P | 2018-04-23 | 2018-04-23 | |
| US62/661,217 | 2018-04-23 | ||
| PCT/US2019/028647 WO2019209787A1 (en) | 2018-04-23 | 2019-04-23 | Inhalable liposomal sustained release composition for use in treating pulmonary diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3101102A1 true CA3101102A1 (en) | 2019-10-31 |
Family
ID=66821301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3101102A Pending CA3101102A1 (en) | 2018-04-23 | 2019-04-23 | Inhalable liposomal sustained release composition for use in treating pulmonary diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11534399B2 (enExample) |
| EP (1) | EP3784213B1 (enExample) |
| JP (1) | JP7391039B2 (enExample) |
| KR (1) | KR20210003197A (enExample) |
| CN (1) | CN112004527B (enExample) |
| AU (1) | AU2019261329B2 (enExample) |
| BR (1) | BR112020021412A8 (enExample) |
| CA (1) | CA3101102A1 (enExample) |
| ES (1) | ES2964413T3 (enExample) |
| IL (1) | IL278079B2 (enExample) |
| TW (1) | TWI866908B (enExample) |
| WO (1) | WO2019209787A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3784213B1 (en) | 2018-04-23 | 2023-09-06 | InspirMed Corp. | Inhalable liposomal sustained release composition for use in treating pulmonary diseases |
| TWI786328B (zh) * | 2018-09-10 | 2022-12-11 | 台灣微脂體股份有限公司 | 緩釋眼用藥物組合物及其用途 |
| US12599557B2 (en) | 2019-04-25 | 2026-04-14 | Tlc Biopharmaceuticals, Inc. | Liposomal sustained-release compositions containing a therapeutic drug and use thereof |
| TWI853932B (zh) * | 2019-05-14 | 2024-09-01 | 盈擘生技股份有限公司 | 用於治療肺部疾病之可吸入的支氣管擴張劑緩釋組成物 |
| WO2021194927A1 (en) * | 2020-03-22 | 2021-09-30 | Tlc Biopharmaceuticals, Inc. | Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases |
| CN112472791A (zh) * | 2020-11-16 | 2021-03-12 | 复旦大学 | CsA脂质体在制备抗SARS-CoV-2药物中的应用 |
| EP4259101A4 (en) * | 2020-12-14 | 2024-11-27 | Nanotech Pharma Inc. | COMPOSITIONS AND METHODS FOR DELIVERY OF ANTICANCER AGENTS WITH IMPROVED THERAPEUTIC INDEX |
| CN114642656B8 (zh) * | 2020-12-18 | 2025-12-12 | 盈科瑞（天津）创新医药研究有限公司 | 一种吸入用尼达尼布溶液及其制备方法 |
| US20250325549A1 (en) * | 2021-08-18 | 2025-10-23 | Samyang Holdings Corporation | Oral tablet composition of ruxolitinib and method for preparing same |
| KR102348901B1 (ko) | 2021-08-26 | 2022-01-07 | 충북대학교 산학협력단 | 레고라페닙을 유효성분으로 포함하는 만성폐쇄성 폐질환의 예방 또는 치료용 조성물 |
| CN116064394A (zh) * | 2021-11-01 | 2023-05-05 | 中国医学科学院医药生物技术研究所 | 肿瘤细胞外泌体与脂质体的杂化外泌体、其制备方法及其抗肿瘤用途 |
| JP2025069482A (ja) * | 2022-03-25 | 2025-05-01 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 特発性肺線維症の治療または予防剤 |
| CN120076792A (zh) * | 2022-09-30 | 2025-05-30 | 上海济昀生物科技有限公司 | 一种脂质体药物组合物及其制备方法和应用 |
| BE1031669B1 (fr) * | 2023-06-02 | 2025-01-14 | Inhatarget Therapeutics | Composition pharmaceutique pour inhalation |
| EP4637764A1 (en) * | 2023-12-22 | 2025-10-29 | Zedira GmbH | Oxo-pyridine derivatives as inhibitors of transglutaminases for use in the treatment of pulmonary fibrosis |
| WO2025138298A1 (zh) * | 2023-12-30 | 2025-07-03 | 北京睿创康泰医药研究院有限公司 | 一种尼达尼布超分子复合体的药物组合物 |
| CN117899020A (zh) * | 2024-01-16 | 2024-04-19 | 中山大学 | 一种载抗生素黏液渗透型脂质体粉雾剂的制备方法及其应用 |
| CN118948812A (zh) * | 2024-08-06 | 2024-11-15 | 北京悦康科创医药科技股份有限公司 | 一种多肽脂质体吸入剂及其制备方法和应用 |
| KR102859152B1 (ko) * | 2024-10-24 | 2025-09-12 | 주식회사 한국리포좀 | 합성 지질 리포좀 기반의 일본 뇌염 바이러스 백신 및 그의 제조방법 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63500175A (ja) | 1985-05-22 | 1988-01-21 | リポソ−ム テクノロジ−，インコ−ポレイテツド | リポソ−ム吸入法および吸入システム |
| IE63869B1 (en) | 1986-11-06 | 1995-06-14 | Res Dev Foundation | Aerosols containing liposomes and method for their preparation |
| US5958378A (en) | 1996-07-03 | 1999-09-28 | Research Development Foundation | High dose liposomal aerosol formulations containing cyclosporin A or budesonide |
| GB9912639D0 (en) | 1999-05-28 | 1999-07-28 | Britannia Pharmaceuticals Ltd | Improvements in and relating to treatment of respiratory conditions |
| DE10214983A1 (de) | 2002-04-04 | 2004-04-08 | TransMIT Gesellschaft für Technologietransfer mbH | Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen |
| DE10237423A1 (de) | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
| PT1581236E (pt) | 2002-10-29 | 2013-12-24 | Insmed Inc | Libertação prolongada de anti-infecciosos |
| US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| EP1628637A2 (en) | 2003-05-30 | 2006-03-01 | Alza Corporation | Method of pulmonary administration of an agent |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP3067047B1 (en) | 2005-12-08 | 2022-04-20 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| US8268347B1 (en) | 2006-10-24 | 2012-09-18 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| US8119156B2 (en) | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| US8071127B2 (en) | 2006-10-24 | 2011-12-06 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
| CN101878229A (zh) * | 2007-09-28 | 2010-11-03 | 巴塞尔大学医院 | 用于治疗癌症的免疫脂质体 |
| US9233971B2 (en) * | 2010-08-26 | 2016-01-12 | Kunyuan Cui | Lipomacrocycles and uses thereof |
| JP2013537172A (ja) | 2010-09-09 | 2013-09-30 | トリフォイリウム エーピーエス | 血管新生阻害剤の気道投与 |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| WO2014121211A2 (en) * | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into liposomes |
| EP3782604A1 (en) * | 2013-07-31 | 2021-02-24 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| KR20150026613A (ko) * | 2013-09-03 | 2015-03-11 | 삼성전자주식회사 | 소수성 물질 및 조영제를 포함하는 리포좀 및 그의 용도 |
| AU2015204558B2 (en) | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| WO2016090111A1 (en) | 2014-12-05 | 2016-06-09 | Vindico NanoBio Technology Inc. | Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors |
| WO2016178064A1 (en) | 2015-05-06 | 2016-11-10 | Suven Life Sciences Limited | Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof |
| US20180344644A1 (en) * | 2015-09-21 | 2018-12-06 | Mallinckrodt Llc | Improved stability of liposome formulations and uses thereof |
| EP4218739A3 (en) * | 2016-01-08 | 2023-08-09 | The Regents of The University of California | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery |
| WO2017136774A1 (en) * | 2016-02-04 | 2017-08-10 | Stem Cell Theranostics, Inc. | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity |
| EP3784213B1 (en) | 2018-04-23 | 2023-09-06 | InspirMed Corp. | Inhalable liposomal sustained release composition for use in treating pulmonary diseases |
-
2019
- 2019-04-23 EP EP19729872.2A patent/EP3784213B1/en active Active
- 2019-04-23 IL IL278079A patent/IL278079B2/en unknown
- 2019-04-23 WO PCT/US2019/028647 patent/WO2019209787A1/en not_active Ceased
- 2019-04-23 ES ES19729872T patent/ES2964413T3/es active Active
- 2019-04-23 BR BR112020021412A patent/BR112020021412A8/pt unknown
- 2019-04-23 KR KR1020207033553A patent/KR20210003197A/ko not_active Ceased
- 2019-04-23 CN CN201980027748.1A patent/CN112004527B/zh active Active
- 2019-04-23 TW TW108114188A patent/TWI866908B/zh active
- 2019-04-23 AU AU2019261329A patent/AU2019261329B2/en active Active
- 2019-04-23 CA CA3101102A patent/CA3101102A1/en active Pending
- 2019-04-23 US US17/045,940 patent/US11534399B2/en active Active
- 2019-04-23 JP JP2020556946A patent/JP7391039B2/ja active Active
-
2022
- 2022-11-22 US US17/992,481 patent/US12533313B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7391039B2 (ja) | 2023-12-04 |
| US20230088661A1 (en) | 2023-03-23 |
| CN112004527A (zh) | 2020-11-27 |
| US11534399B2 (en) | 2022-12-27 |
| EP3784213B1 (en) | 2023-09-06 |
| EP3784213C0 (en) | 2023-09-06 |
| JP2021522163A (ja) | 2021-08-30 |
| TW202011941A (zh) | 2020-04-01 |
| IL278079A (en) | 2020-11-30 |
| ES2964413T3 (es) | 2024-04-05 |
| CN112004527B (zh) | 2024-09-24 |
| KR20210003197A (ko) | 2021-01-11 |
| IL278079B2 (en) | 2025-08-01 |
| EP3784213A1 (en) | 2021-03-03 |
| US20210145740A1 (en) | 2021-05-20 |
| AU2019261329B2 (en) | 2024-09-05 |
| US12533313B2 (en) | 2026-01-27 |
| BR112020021412A8 (pt) | 2022-07-05 |
| BR112020021412A2 (pt) | 2021-01-19 |
| TWI866908B (zh) | 2024-12-21 |
| WO2019209787A1 (en) | 2019-10-31 |
| AU2019261329A1 (en) | 2020-11-12 |
| IL278079B1 (en) | 2025-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12533313B2 (en) | Inhalable liposomal sustained release composition for use in treating pulmonary diseases | |
| JP4885715B2 (ja) | イリノテカン製剤 | |
| CN116635009A (zh) | 用于递送抗癌剂的具有改进的治疗指数的组合物和方法 | |
| CN103479578A (zh) | 一种马来酸匹杉琼的脂质体制剂及其制备工艺 | |
| US20260108534A1 (en) | Liposomal formulations of bcl inhibitors | |
| KR20220156861A (ko) | 감염성 또는 호흡기 질병의 예방 또는 노출 후 치료에 사용하기 위한 항바이러스제의 조성물 | |
| TWI853932B (zh) | 用於治療肺部疾病之可吸入的支氣管擴張劑緩釋組成物 | |
| HK40043569A (en) | Inhalable liposomal sustained release composition for use in treating pulmonary diseases | |
| WO2022074181A1 (en) | Nanocarrier formulations for inhalation | |
| HK40043569B (zh) | 用於治疗肺部疾病的可吸入脂质体缓释组合物 | |
| KR20240037264A (ko) | Bcl 억제제의 리포솜 제형 | |
| HK40054349A (en) | Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231218 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241021 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241021 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241021 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250203 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250520 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250520 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250723 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250723 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260121 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260318 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260326 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260326 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260326 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260401 |